Clinical trials: Arthritis, Rheumatoid (RA)
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid…
- Trial name
- NCT02089087
- Testing
- CFZ533
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)
Participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - 50…
- Trial name
- NCT01894516
- Testing
- GLPG0634
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 287 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
Cortisol Circadian Rhythm in Patients With RA
The European League Against Rheumatism (EULAR), acknowledging the critical issue of the complications, of long term treatment with glucocorticoids in the most recent update of the management guidelines for Rheumatoid arthritis…
- Trial name
- CortRyRA (NCT05671627)
- Testing
- DMARDs
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Rheumatoid Arthritis (RA)
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis…
- Trial name
- NCT03660059
- Testing
- Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 385 people
- Sponsor
- Astellas Pharma China, Inc.
Rheumatoid Arthritis, Healthy Volunteers
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib…
- Conditions
- Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone
- Trial name
- NCT01309854
- Testing
- fostamatinib, pioglitazone
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)
The purpose of this study is to explore the differences in productivity loss and costs between patients being treated for rheumatoid arthritis (RA) with biologic disease-modifying antirheumatic drugs (bDMARDs) compared to…
- Trial name
- NCT01136694
- Volunteers
- 695 people
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers, Rheumatoid Arthritis
Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects
The purpose of this study is to investigate the drug interaction between fostamatinib and digoxin by comparing the safety, tolerability and plasma concentration of digoxin when administered alone and with fostamatinib in healthy…
- Trial name
- NCT01355354
- Testing
- Digoxin, Fostamatinib
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy.
- Trial name
- FEATURE (NCT00673920)
- Testing
- Methotrexate, Ocrelizumab
- Volunteers
- 314 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.
This observational study will describe the treatment patterns of usage of biological DMARDs in routine clinical practice and the demographics and RA disease characteristics in patients suffering from rheumatoid arthritis.
- Trial name
- NCT02590562
- Testing
- Routine clinical practice
- Where
- 15 sites in China
- Volunteers
- 808 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
This open-label, single arm, Phase 3b study will evaluate the efficacy of tocilizumab (RoActemra), administered as monotherapy or in combination with methotrexate and/or other DMARDs, in participants with moderate to severe…
- Trial name
- NCT01941940
- Testing
- Tocilizumab, DMARDs
- Where
- 49 sites in Italy
- Volunteers
- 227 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics
This is a single site study to determine the structural efficacy of sarilumab when administered to biologic naive patients with active rheumatoid arthritis
- Trial name
- NCT03535402
- Testing
- Sarilumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gaylis, Norman B., M.D.
Rheumatoid Arthritis (RA)
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib [UPA]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)…
- Trial name
- NCT03682705
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 115 sites in United States, Belgium and 7 more
- Volunteers
- 242 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
The purpose of the study is to evaluate the improvements in signs and symptoms of rheumatoid arthritis (RA) for fostamatinib compared to placebo or adalimumab in patients who are Disease-Modifying anti-rheumatic drug (DMARD)…
- Trial name
- OSKIRA -4 (NCT01264770)
- Where
- 105 sites in United States, Bulgaria and 11 more
- Volunteers
- 644 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
The Treat-to-target Study of RA Based on Smart System of Disease Management(SSDM)
This study evaluate the Smart System of Disease Management（SSDM）to improve the treat-to-target(T2T) and the safety of drug in the treatment of rheumatoid(RA).
- Trial name
- T2TRAonSSDM (NCT03715595)
- Testing
- SSDM group
- Where
- China
- Volunteers
- 2,200 people
- Sponsor
- Peking University People's Hospital
Rheumatoid Arthritis
A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s…
- Trial name
- NCT00195403
- Testing
- Etanercept
- Where
- 4 sites in South Korea
- Volunteers
- 1,014 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in…
- Trial name
- NCT00154336
- Testing
- Imatinib, Methotrexate
- Where
- 15 sites in Austria, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
Treatments Against RA and Effect on FDG-PET/CT
In a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA)…
- Trial name
- TARGET (NCT02374021)
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- 31 sites in United States
- Volunteers
- 159 people
- Sponsor
- Brigham and Women's Hospital
Rheumatoid Arthritis, Pain
Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients
The purpose of this study is to investigate how RA affect the brain structures in RA-patients and if anti-inflammatory treatment that target TNF-α or JAK OR physical training of hands has positive impact on neuropsychiatric…
- Conditions
- Rheumatoid Arthritis, Pain, Fatigue, Cognitive Decline
- Trial name
- NeuMRA (NCT04378621)
- Testing
- TNF-α inhibitor OR JAK inhibitor, Hand training
- Where
- Sweden
- Volunteers
- 212 people
- Sponsor
- Vastra Gotaland Region
Rheumatoid Arthritis
A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already…
- Trial name
- ESCAPE (NCT00713544)
- Testing
- AZD5672, Etanercept
- Where
- 49 sites in Bulgaria, Colombia and 12 more
- Volunteers
- 373 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics